FDA承認 ブリッジビオのアトルービー ATT心筋アミロイド症 死亡と入院率を42%減少 FDA approves BridgeBio's Attruby for ATTR cardiac amyloidosis, reducing deaths and hospitalizations by 42%.

BridgeBio PharmaのAttrubyTMは,ATTR- 心臓アミロイドーシスを持つ成人の治療にFDAの承認を受け,心血管疾患による死亡と入院を減少させました. BridgeBio Pharma's Attruby™ has received FDA approval for treating adults with ATTR-cardiac amyloidosis, reducing cardiovascular death and hospitalizations. 完全に近いトランスチレチンの安定性を示す最初の製品で,第3相試験で有意な効果を示した. It is the first product to stabilize transthyretin near completely, showing significant benefits in a Phase 3 study. 死亡と入院率を42%下げ 生活の質も向上した Attruby reduced death and hospitalization by 42% and improved quality of life. 承認はまた,ブリッジビオに5億ドルの支払いを促す。 The approval also triggers a $500 million payment for BridgeBio.